Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
暂无分享,去创建一个
Shouhao Zhou | Ying Xu | Chan Shen | Shouhao Zhou | James C Yao | T. Shih | A. Dasari | Chan Shen | D. Halperin | Bo Zhao | Ying Xu | Arvind Dasari | James C. Yao | Daniel Halperin | Bo Zhao | Tina Shih | J. Yao
[1] Y. Bang,et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[2] A. Scarpa,et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system , 2007, Virchows Archiv.
[3] Domenico Coppola,et al. The Pathologic Classification of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and Staging Systems , 2010, Pancreas.
[4] James C Yao,et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study , 2016, The Lancet.
[5] R. Saskin,et al. Exploring the rising incidence of neuroendocrine tumors: A population‐based analysis of epidemiology, metastatic presentation, and outcomes , 2015, Cancer.
[6] J. Berlin,et al. Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.
[7] Jeffrey W. Clark,et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A R Feinstein,et al. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. , 1985, The New England journal of medicine.
[9] C. Schade-Brittinger,et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Manal M. Hassan,et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Kerr. Oral regimen for metastatic neuroendocrine tumours. , 2006, The Lancet Oncology.
[12] D.,et al. Regression Models and Life-Tables , 2022 .
[13] B. Weinhold. Epigenetics: The Science of Change , 2006, Virchows Archiv.
[14] E. D. de Vries,et al. Everolimus for advanced pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[15] S. Lamberts,et al. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. , 2016, Endocrine-related cancer.
[16] A. Faggiano,et al. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. , 2014, Endocrine-related cancer.
[17] Feng Yang,et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. , 2014, The New England journal of medicine.
[18] Seth D. Crockett,et al. Burden of gastrointestinal disease in the United States: 2012 update. , 2012, Gastroenterology.
[19] C. Schade-Brittinger,et al. Placebo-Controlled , Double-Blind , Prospective , Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors : A Report From the PROMID Study Group , 2009 .
[20] R. Pearson. Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2011 .
[21] Nilay D Shah,et al. Trends in Computed Tomography Utilization Rates: A Longitudinal Practice-Based Study , 2014, Journal of patient safety.
[22] Norbert J. Pelc,et al. Recent and Future Directions in CT Imaging , 2014, Annals of Biomedical Engineering.
[23] G. Petersen,et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] E. Krenning,et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.